Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02669056
Other study ID # 2015-35
Secondary ID RCAPHM15_0265
Status Completed
Phase N/A
First received
Last updated
Start date December 17, 2015
Est. completion date May 12, 2023

Study information

Verified date May 2023
Source Assistance Publique Hopitaux De Marseille
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Although significant advances in neonatal care have increased survival rates of preterm infants born before 28 weeks gestation, a concomitant decrease in neuro developmental disorders has not been achieved. Cerebral injuries, well documented during the previous years, in preterm babies are particularly deleterious since they occur in a developing brain. They affect both white and grey matter by complex mechanisms and the principal targets are the developing oligodendrocytes and neurons of the subplate. All these criteria define the encephalopathy of prematurity. Nevertheless, the consequences of prematurity at the level of the brainstem are not very well known and may explain neuro-developmental disorders with normal MRI. The assessment of the motor repertoire is complementary to the neurological examination and may represent a diagnostic tool for cerebral palsy, mild motor deficits and delayed acquisition in children. The newborn have a rich motor repertoire. GMs play a key role in the development due to the feedback that they send to cortical neurons and reflect the maturational stage of the Central Nervous System (CNS). Lesions of the brainstem caused by prematurity may induce alterations of the motor repertoire. Dysautonomic disorders, such as bradycardia, apneas, feeding problems, that occur frequently in very preterm babies reflect brainstem abnormalities. These symptoms are also described in other pathologies, in Rett syndrome and sudden infant death syndrome (SIDS). In these pathologies deficits of the 5-HT system have been described and associated with dysautonomia. It would then be interesting to evaluate 5-hydroxytryptamine (5-HT) levels in very preterm babies. The serotonergic system develops very early during gestation and is one of the first neurotransmitter to appear in the developing brain. The main 5-HT nuclei are located within the brainstem. 5-HT plays an important role in the homeostasis and the modulation of the respiratory network. Moreover, previous studies have shown that 5-HT projections to the spinal cord are involved in posture and in the coordination. It is tempting to think that 5-HT deficits may have some repercussions on the development of the CNS, changing activity dependent processes, such as spontaneous activity recorded at the spinal level in rodents. In this project, the 5-HT platelet levels in preterm infants born before 28 weeks will be compared with newborns. a correlation between the levels of 5-HT with MRI of the posterior fossa, GMs and dysautonomia different parameters such as heart rate variability, suction-swallowing and different breathing techniques will be established


Recruitment information / eligibility

Status Completed
Enrollment 34
Est. completion date May 12, 2023
Est. primary completion date January 1, 2019
Accepts healthy volunteers No
Gender All
Age group N/A to 28 Weeks
Eligibility Inclusion Criteria: - Birth less than 28 weeks - known gestational age - Birth in born - Infant without genetic syndrom, evolutive neurologic disease, chronic disorder, malformative pathology - Infant without intra-ventricular haemorrhage with dilatation or intraparenchymal haemorrhage - Infants without mechanical ventilation Exclusion Criteria: • Infant with congenital cardiopathy, congenital brainstem disorder, Pierre Robin sequence

Study Design


Related Conditions & MeSH terms


Intervention

Other:
5-HT measurement

cerebral MRI

Video recording

EEG

growth curves

ASQ questionnaire


Locations

Country Name City State
France Assistance Publique Hôpitaux de Marseille Marseille

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique Hopitaux De Marseille

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary 5-HT levels 5-HT platelets levels will be measured in very preterm and in term infants and compared (5-HT platelets level reflect the central 5HT level. term age (37 weeks)
Secondary Posterior fossa injury MRI will be performed at term age to analyse preterm cerebral structure focusing on the posterior fossa at term age (37 weeks)
Secondary General movements (GMs) assesment GMs will be video taped at during the writing movements period and fidgety period and analyzed to detect abnormal GMs 3 times in the hospitalization period and at 3 month post-term age
Secondary R-R variability assesment The autonomic nervous system activity level will be assessed by R-R variability analyze during polysomnographic recordings at 36 weeks
Secondary Respiratory pattern assessment Respiratory pattern assessment will be analyzed during polysomnographic recordings to detect apneas, sighs… at 36 weeks
Secondary Ages and Stages Questionnaires (ASQ) ASQ questionnaire as neurodevelopmental assessment will be send to parents 12 and 24 month post-term age
Secondary weight and statural growth assessment until 24 month postterm age
Secondary statural growth assessment until 24 month postterm age
Secondary Hospitalization duration 6 months